A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks
A Randomised, Open Label, Active Controlled Trial to Evaluate the Antiviral Efficacy and Safety of Treatment With 500 mg Tipranavir Plus 100 mg or 200 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Comparison to 400 mg Lopinavir Plus 100 mg Ritonavir p.o. BID in Combination With Standard Background Regimen in Antiretroviral Therapy Naive Patients for 48 With Extension up to 156 Weeks
Evaluation of safety and efficacy of Tipranavir (TPV) boosted with Ritonavir (RTV) versus an active control arm (Lopinavir / RTV) in antiretroviral (ARV) therapy naïve HIV-1 infected patients
Inclusion Criteria:
Exclusion criteria:
Female patients of child-bearing potential who:
Use of investigational medications within 30 days before study entry or during the trial
BsAs, Argentina
Campinas - Sp, Brazil
Curitiba - PR, Brazil
Manguinhos - Rio de Janeiro - RJ, Brazil
Mooca / São Paulo, Brazil
Nova Iguaçu - RJ, Brazil
Rio de Janeiro - RJ, Brazil
Sacoma - São Paulo, Brazil
Salvador - BA, Brazil
Santos - Sp, Brazil
São Paulo - Sp, Brazil
São Paulo - SP, Brazil
São Paulo - SP, Brazil
São Paulo - Sp, Brazil
Vila Mariana - Sao Paulo, Brazil
Monteal, Quebec, Canada
Col. Villaseñor, Guadalajara, Jal., Mexico